Fig. 3From: Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in ChinaQuantitative changes of IHC indicators. A Changes of ER expression. B Changes of PR expression. C Changes of Ki-67 expression. D Changes of HER2 expressionBack to article page